| Time Span Codes Policy, Professional | Commercial | 30 | Original policy ↗ |
| Tocilizumab Injection for Intravenous Infusion | 2026D0043Z · Effective Jul 1, 2026 · Commercial | 4 | Original policy ↗ |
| Total Artificial Disc Replacement for the Spine | 2026T0437PP · Effective Feb 1, 2026 · Commercial | 9 | Original policy ↗ |
| Transarterial Radioembolization (TARE)/ Selective Internal Radiation Therapy (SIRT) for the Treatment of Malignant Cancers of the Liver | 2026T0445BB · Effective Jan 1, 2026 · Commercial | 4 | Original policy ↗ |
| Transcatheter Procedures for Heart Valve Conditions | 2026T0557FF · Effective Jul 1, 2026 · Commercial | 25 | Original policy ↗ |
| Transcranial Magnetic Stimulation for Treating Physical Health Conditions | 2026T0536W · Effective Feb 1, 2026 · Commercial | 8 | Original policy ↗ |
| Treatment of Temporomandibular Joint (TMJ) | MMP025.14 · Effective Aug 1, 2026 | 49 | Original policy ↗ |
| Treatment of Temporomandibular Joint Disorders | 2026T0079SS · Effective Oct 1, 2026 · Commercial | 19 | Original policy ↗ |
| Tremfya® (Guselkumab) | 2026D0134D · Effective May 1, 2026 · Commercial | 2 | Original policy ↗ |
| Trogarzo® (Ibalizumab-Uiyk) | 2026D0063K · Effective Jun 1, 2026 · Commercial | 1 | Original policy ↗ |
| Tzield® (Teplizumab-Mzwv) | 2026D0117J · Effective Oct 1, 2026 · Commercial | 1 | Original policy ↗ |
| Umbilical Cord Blood Harvesting and Storage for Future Use | 2026T0109CC · Effective Jul 1, 2026 · Commercial | 5 | Original policy ↗ |
| UnitedHealthcare Commercial Medical Policy Update Bulletin Archive | Commercial | — | Original policy ↗ |
| UnitedHealthcare Commercial Medical Policy Update Bulletin: August 2026 | Effective Aug 1, 2026 · Commercial | — | Original policy ↗ |
| UnitedHealthcare Commercial Medical Policy Update Bulletin: October 2026 | Effective Oct 1, 2026 · Commercial | — | Original policy ↗ |
| UnitedHealthcare Commercial Medical Policy Update Bulletin: September 2026 | Commercial | — | Original policy ↗ |
| UnitedHealthcare Commercial Reimbursement Policy Update Bulletin: April 2026 | Effective Apr 1, 2026 · Commercial | — | Original policy ↗ |
| UnitedHealthcare Commercial Reimbursement Policy Update Bulletin: August 2026 | Effective Aug 1, 2026 · Commercial | — | Original policy ↗ |
| UnitedHealthcare Commercial Reimbursement Policy Update Bulletin: December 2024 | Effective Dec 1, 2024 · Commercial | 8 | Original policy ↗ |
| UnitedHealthcare Commercial Reimbursement Policy Update Bulletin: February 2026 | Effective Feb 1, 2026 · Commercial | 1 | Original policy ↗ |
| UnitedHealthcare Commercial Reimbursement Policy Update Bulletin: July 2026 | Effective Jul 1, 2026 · Commercial | — | Original policy ↗ |
| UnitedHealthcare Commercial Reimbursement Policy Update Bulletin: June 2026 | Commercial | 1 | Original policy ↗ |
| UnitedHealthcare Commercial Reimbursement Policy Update Bulletin: March 2026 | Commercial | — | Original policy ↗ |
| UnitedHealthcare Commercial Reimbursement Policy Update Bulletin: May 2026 | Effective May 1, 2026 · Commercial | — | Original policy ↗ |
| UnitedHealthcare Commercial Reimbursement Policy Update Bulletin: October 2026 | Effective Oct 1, 2026 · Commercial | 2 | Original policy ↗ |
| UnitedHealthcare Commercial Reimbursement Policy Update Bulletin: September 2026 | Effective Sep 1, 2026 · Commercial | — | Original policy ↗ |
| UnitedHealthcare Community Plan of Michigan Prior authorization and notification | Medicaid | — | Original policy ↗ |
| UnitedHealthcare Medicare Advantage/ Peoples Health and Rocky Mountain Health Plans prior authorization requirements | Effective Jan 1, 2026 · Medicaid | 1,534 | Original policy ↗ |
| Uplizna® (Inebilizumab-Cdon) – Commercial Medical Benefit Drug Policy | 2026D0091J · Effective Apr 1, 2026 · Commercial | 1 | Original policy ↗ |
| Upper Extremity Prosthetic Devices | 2026T0641I · Effective Apr 1, 2026 · Commercial | 62 | Original policy ↗ |
| Urgent Care Policy, Professional | Effective Aug 1, 2026 · Commercial | 2 | Original policy ↗ |
| Urinary and Fecal Incontinence: Diagnosis and Treatment | MMP049.14 · Effective Sep 1, 2026 | 8 | Original policy ↗ |
| Urogenital/Anogenital (UG/AG) Panels | MMP373.34 · Effective Aug 1, 2026 | 5 | Original policy ↗ |
| Ustekinumab | 2026D0045AB · Effective Jul 1, 2026 · Commercial | 15 | Original policy ↗ |
| Uterine Services and Procedures | MMP098.11 · Effective Sep 1, 2026 | 27 | Original policy ↗ |
| Vagus and External Trigeminal Nerve Stimulation | 2026T0101NN · Effective Jan 1, 2026 · Commercial | 18 | Original policy ↗ |
| Varicose Veins Treatment and Other Vein Embolization Procedures | MMP099.11 · Effective Sep 1, 2026 | 3 | Original policy ↗ |
| Veopoz® (Pozelimab-Bbfg) | 2026D0128E · Effective May 1, 2026 · Commercial | 1 | Original policy ↗ |
| Vertebral Body Tethering for Scoliosis – Commercial and Individual Exchange Medical Policy | 2026T0605M · Commercial | 7 | Original policy ↗ |
| Video Electroencephalographic (vEEG) Monitoring and Recording | 2026T0596P · Effective Jan 1, 2026 · Commercial | 12 | Original policy ↗ |
| Viltepso® (Viltolarsen) | 2026D0095J · Effective May 1, 2026 · Commercial | 1 | Original policy ↗ |
| Visual Information Processing Evaluation and Orthoptic and Vision Therapy | 2026T0072FF · Effective Jan 1, 2026 · Commercial | 8 | Original policy ↗ |
| Vitamin B12 Testing Policy, Professional and Facility | 2026R8014A · Effective Sep 1, 2026 · Commercial | 2 | Original policy ↗ |
| Vitamin D Testing | MMP377.14 · Effective Sep 1, 2026 | 1 | Original policy ↗ |
| Vyepti® (Eptinezumab-Jjmr) | 2026D0090N · Effective Sep 1, 2026 · Commercial | 1 | Original policy ↗ |
| Vyjuvek® (Beramagene Geperpavec-Svdt) | 2026D0127G · Effective Jan 1, 2026 · Commercial | 1 | Original policy ↗ |
| Vyondys 53® (Golodirsen) | 2026D0088I · Effective May 1, 2026 · Commercial | 1 | Original policy ↗ |
| White Blood Cell Colony Stimulating Factors | 2026D0061AE · Effective Sep 1, 2026 · Commercial | 20 | Original policy ↗ |
| Whole Exome and Whole Genome Sequencing (Non-Oncology Conditions) | 2026T0589BB · Effective Oct 1, 2026 · Commercial | 39 | Original policy ↗ |
| Wrong Surgical or Other Invasive Procedures Policy, Professional and Facility | Commercial | — | Original policy ↗ |